Switch theme
Sign up to access all valuation multiples
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
1998
34
LTM Revenue n/a
LTM EBITDA n/a
-$2.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Epigenomics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Epigenomics achieved revenue of $0.5M and an EBITDA of -$12.1M.
Epigenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Epigenomics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.7M | $0.5M | XXX | XXX | XXX |
| Gross Profit | n/a | $6.5M | XXX | XXX | XXX |
| Gross Margin | NaN% | 1251% | XXX | XXX | XXX |
| EBITDA | -$2.1M | -$12.1M | XXX | XXX | XXX |
| EBITDA Margin | -31% | -2314% | XXX | XXX | XXX |
| Net Profit | n/a | -$2.6M | XXX | XXX | XXX |
| Net Margin | NaN% | -501% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Epigenomics's stock price is EUR 1 (or $1).
Epigenomics has current market cap of EUR 0.8M (or $0.8M), and EV of -EUR 2.5M (or -$2.6M).
See Epigenomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$2.6M | $0.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Epigenomics has market cap of $0.8M and EV of -$2.6M.
Epigenomics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Epigenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Epigenomics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$2.6M | XXX | XXX | XXX |
| EV/Revenue | -5.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | XXX | XXX |
| P/E | -0.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEpigenomics's NTM/LTM revenue growth is n/a
Epigenomics's revenue per employee for the last fiscal year averaged $15K, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Epigenomics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Epigenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Epigenomics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -92% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2314% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 479% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $15K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 886% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1276% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2727% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Epigenomics acquired XXX companies to date.
Last acquisition by Epigenomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Epigenomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Epigenomics founded? | Epigenomics was founded in 1998. |
| Where is Epigenomics headquartered? | Epigenomics is headquartered in Germany. |
| How many employees does Epigenomics have? | As of today, Epigenomics has 34 employees. |
| Is Epigenomics publicy listed? | Yes, Epigenomics is a public company listed on FRA. |
| What is the stock symbol of Epigenomics? | Epigenomics trades under ECX ticker. |
| When did Epigenomics go public? | Epigenomics went public in 2014. |
| Who are competitors of Epigenomics? | Similar companies to Epigenomics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Epigenomics? | Epigenomics's current market cap is $0.8M |
| What is the current revenue growth of Epigenomics? | Epigenomics revenue growth between 2023 and 2024 was -92%. |
| Is Epigenomics profitable? | Yes, Epigenomics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
